Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

 Full screen view
Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
HME1 Tivantinib
0.1
MET
RTK
 0.0360 0.28655
HME1 Tivantinib
0.31623
MET
RTK
 -0.1213 0.32977
HME1 Tivantinib
1.0
MET
RTK
 -0.1181 0.36459
HME1 Tivantinib
3.1623
MET
RTK
 -0.1308 0.42862
HME1 Tivantinib
10.0
MET
RTK
 -0.1612 0.44114
HME1 Cediranib
0.001
VEGFR/cKIT
RTK
 1.0678 0.00264
HME1 Cediranib
0.0031623
VEGFR/cKIT
RTK
 1.0942 0.00158
HME1 Cediranib
0.01
VEGFR/cKIT
RTK
 1.0882 0.00363
HME1 Cediranib
0.031623
VEGFR/cKIT
RTK
 1.1129 -0.00121
HME1 Cediranib
0.1
VEGFR/cKIT
RTK
 1.1080 0.00358
HME1 Cediranib
0.31623
VEGFR/cKIT
RTK
 1.0962 0.00312
HME1 Cediranib
1.0
VEGFR/cKIT
RTK
 1.1291 0.00336
HME1 Cediranib
3.1623
VEGFR/cKIT
RTK
 0.9898 0.00021
HME1 Cediranib
10.0
VEGFR/cKIT
RTK
 0.0275 0.20231
HME1 Cabozantinib
0.001
VEGFR2/MET
RTK
 1.0351 0.00073
HME1 Cabozantinib
0.0031623
VEGFR2/MET
RTK
 1.0834 0.00218
HME1 Cabozantinib
0.01
VEGFR2/MET
RTK
 1.0751 0.00001
HME1 Cabozantinib
0.031623
VEGFR2/MET
RTK
 1.0964 0.00018
HME1 Cabozantinib
0.1
VEGFR2/MET
RTK
 1.0687 0.00256
HME1 Cabozantinib
0.31623
VEGFR2/MET
RTK
 1.0399 0.01058
HME1 Cabozantinib
1.0
VEGFR2/MET
RTK
 0.9599 0.00869
HME1 Cabozantinib
3.1623
VEGFR2/MET
RTK
 0.5190 0.02233
HME1 Cabozantinib
10.0
VEGFR2/MET
RTK
 -0.1052 0.18653
SUM1315MO2 Abemaciclib
0.001
CDK4/6
Cell cycle
 1.0408 0.00466
SUM1315MO2 Abemaciclib
0.0031623
CDK4/6
Cell cycle
 0.7932 0.00034